MX340739B - Quimeras ospa y su uso en vacunas. - Google Patents

Quimeras ospa y su uso en vacunas.

Info

Publication number
MX340739B
MX340739B MX2012013264A MX2012013264A MX340739B MX 340739 B MX340739 B MX 340739B MX 2012013264 A MX2012013264 A MX 2012013264A MX 2012013264 A MX2012013264 A MX 2012013264A MX 340739 B MX340739 B MX 340739B
Authority
MX
Mexico
Prior art keywords
ospa
chimeric molecules
vaccines
serotype
ospa chimeras
Prior art date
Application number
MX2012013264A
Other languages
English (en)
Spanish (es)
Other versions
MX2012013264A (es
Inventor
A Crowe Brian
Livey Ian
O'rourke Maria
Schwendinger Michael
J Dunn John
J Luft Benjamin
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of MX2012013264A publication Critical patent/MX2012013264A/es
Publication of MX340739B publication Critical patent/MX340739B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2012013264A 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas. MX340739B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
PCT/US2011/036533 WO2011143623A1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Publications (2)

Publication Number Publication Date
MX2012013264A MX2012013264A (es) 2014-12-05
MX340739B true MX340739B (es) 2016-07-22

Family

ID=44121257

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012013264A MX340739B (es) 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas.
MX2012013261A MX348113B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2012013261A MX348113B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Country Status (13)

Country Link
US (6) US8623375B2 (enExample)
EP (4) EP2569008B1 (enExample)
JP (6) JP6030052B2 (enExample)
KR (7) KR102130584B1 (enExample)
CN (3) CN103118701B (enExample)
AU (2) AU2011252844B2 (enExample)
BR (2) BR112012029058B1 (enExample)
CA (2) CA2799181C (enExample)
MX (3) MX340739B (enExample)
PL (2) PL2569008T3 (enExample)
RU (2) RU2636455C2 (enExample)
SI (2) SI2569009T1 (enExample)
WO (2) WO2011143623A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
US8571937B2 (en) 2010-10-20 2013-10-29 Playspan Inc. Dynamic payment optimization apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
CN105229023B (zh) * 2013-03-15 2019-08-16 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
HRP20250954T1 (hr) * 2014-01-09 2025-10-10 Valneva Austria Gmbh Mutantni fragmenti ospa i postupci i upotrebe koji se na njih odnose
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
KR20200047751A (ko) * 2015-08-14 2020-05-07 텔레호낙티에볼라게트 엘엠 에릭슨(피유비엘) 패킷 데이터 네트워크 연결을 관리하기 위한 노드 및 방법
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
EP3609911B1 (en) * 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
US20230398210A1 (en) 2020-04-09 2023-12-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
EP4132950A1 (en) * 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
KR20230121863A (ko) 2020-12-17 2023-08-21 아이덱스 래보러토리즈, 인코포레이티드 로키산 홍반열 검출 및 치료
EP4351777A4 (en) * 2021-06-07 2025-04-16 The University of Massachusetts Apparatus and method for the continuous production of RNA
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0536335A4 (en) * 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE168132T1 (de) 1991-02-15 1998-07-15 Uab Research Foundation Strukturgen von pneumokokken-protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995012676A1 (en) * 1993-11-01 1995-05-11 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
CA2244110A1 (en) 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
ES2270523T3 (es) 1997-06-30 2007-04-01 The Administrators Of The Tulane Educational Fund Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
DE60131858T2 (de) * 2000-08-18 2008-12-04 The Research Foundation Of State University Of New York Borrelia burgdorferi rekombinante genkonstrukte
AU2001285049A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
WO2004089969A2 (en) 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BRPI0509079B8 (pt) * 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
US7794727B2 (en) 2005-11-29 2010-09-14 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US8293876B2 (en) 2007-02-22 2012-10-23 Baxter International Inc. Method of purification of hydrophobic proteins
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101909635B (zh) * 2008-01-11 2014-09-17 Vgx药品有限责任公司 针对多种登革病毒亚型的新颖疫苗
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof

Also Published As

Publication number Publication date
CN103108652A (zh) 2013-05-15
CA2798331C (en) 2022-03-15
KR20180031814A (ko) 2018-03-28
BR112012027315A2 (pt) 2016-11-16
SI2569008T1 (sl) 2020-02-28
KR20130133120A (ko) 2013-12-06
JP2013529078A (ja) 2013-07-18
JP6227407B2 (ja) 2017-11-08
RU2012153972A (ru) 2014-06-20
US20180296656A1 (en) 2018-10-18
AU2011252850A1 (en) 2012-11-29
US8623375B2 (en) 2014-01-07
JP2016168057A (ja) 2016-09-23
AU2011252850B2 (en) 2016-03-17
MX2012013264A (es) 2014-12-05
US20140141029A1 (en) 2014-05-22
US9334311B2 (en) 2016-05-10
AU2011252844A1 (en) 2012-11-29
CN103118701A (zh) 2013-05-22
RU2583289C2 (ru) 2016-05-10
AU2011252844B2 (en) 2014-07-03
CA2798331A1 (en) 2011-11-17
WO2011143617A1 (en) 2011-11-17
US8623376B2 (en) 2014-01-07
JP2013529077A (ja) 2013-07-18
KR102085465B1 (ko) 2020-03-05
US20120020973A1 (en) 2012-01-26
BR112012029058B1 (pt) 2022-03-29
KR102230562B1 (ko) 2021-03-22
EP2569009A1 (en) 2013-03-20
CA2799181C (en) 2023-10-24
US9895434B2 (en) 2018-02-20
KR102130584B1 (ko) 2020-07-07
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
US9303073B2 (en) 2016-04-05
EP3705133A3 (en) 2021-01-06
PL2569009T3 (pl) 2020-06-15
US11305000B2 (en) 2022-04-19
RU2012153752A (ru) 2014-06-20
KR102222869B1 (ko) 2021-03-04
BR112012029058A2 (pt) 2020-06-23
MX2012013261A (es) 2013-04-19
CN107641151B (zh) 2021-10-01
CN107641151A (zh) 2018-01-30
CA2799181A1 (en) 2011-11-17
JP2020178719A (ja) 2020-11-05
JP2016171816A (ja) 2016-09-29
JP6965417B2 (ja) 2021-11-10
BR112012027315B1 (pt) 2021-08-17
EP3650041A1 (en) 2020-05-13
JP2018150386A (ja) 2018-09-27
KR20130062954A (ko) 2013-06-13
CN103108652B (zh) 2016-05-11
US20160235830A1 (en) 2016-08-18
EP2569008A1 (en) 2013-03-20
KR20200084062A (ko) 2020-07-09
US20110293652A1 (en) 2011-12-01
WO2011143623A1 (en) 2011-11-17
KR20190027955A (ko) 2019-03-15
MX375965B (es) 2025-03-07
EP3705133A2 (en) 2020-09-09
RU2636455C2 (ru) 2017-11-23
KR20180082633A (ko) 2018-07-18
EP2569008B1 (en) 2019-12-25
EP2569009B1 (en) 2019-10-09
KR20200024354A (ko) 2020-03-06
MX348113B (es) 2017-05-29
RU2017138652A3 (enExample) 2021-03-15
EP3705133B1 (en) 2024-06-26
JP6030052B2 (ja) 2016-11-24
BR112012027315A8 (pt) 2020-09-01
RU2017138652A (ru) 2019-02-11
US20140141030A1 (en) 2014-05-22
CN103118701B (zh) 2017-10-24

Similar Documents

Publication Publication Date Title
MX2012013264A (es) Quimeras ospa y su uso en vacunas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
BR112013018416A2 (pt) dispositivos médicos infláveis
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HUE042825T2 (hu) Citidin-analógokat tartalmazó orális készítmények, és eljárás azok alkalmazására
BRPI0908936A2 (pt) vacinas de flavivírus de replicação defeituosa e vetores de vacina
BRPI1014494A2 (pt) vacina pneumocócica e usos da mesma
IL216550A (en) Immunomodulatory agent-polymeric compounds, compositions comprising them, methods for their production and their uses
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
WO2013078402A3 (en) Tissue and stone removal device
BR112014013140A8 (pt) cosmética de prótese
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
BR112015001313A2 (pt) composições de vacina
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
WO2013166478A3 (en) Surgical instruments for oct assisted procedures
CL2011003043A1 (es) Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
EP2437778A4 (en) RECOMBINANT WESTNILVIRUS SUBSIDIARY VACCINE FOR THE PROTECTION OF HUMAN LIFE
BR112015013374A2 (pt) dispositivo de luva hemostática e método para uso do mesmo
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
BR112015020079A8 (pt) Composições para cuidado oral

Legal Events

Date Code Title Description
FG Grant or registration